Furthermore, Sen et al. demonstrated that MYC overexpression in SCLC models is linked to increased sensitivity to prexasertib, particularly when used in combination with cisplatin or the PARP inhibitor Olaparib, highlighting the importance of selecting patients based on genetic biomarkers to predict therapy responsiveness in specific patient populations [123]. This evidence concerns the gene PARP1 and small cell lung carcinoma.